Mutational profiles and prognostic impact in colorectal and high‐grade appendiceal adenocarcinoma with peritoneal metastases
Journal of Surgical Oncology · 2023
DOI: 10.1002/jso.27203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2023. Verfasst von Ryan B Morgan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Biological Sciences Division, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Appendiceal Neoplasms, Peritoneal Neoplasms, Hyperthermia, Induced. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
Next‐generation sequencing (NGS) personalizes cancer treatments. In this study, we analyze outcomes based on NGS testing for colorectal cancer (CRC) and high‐grade appendiceal adenocarcinoma (HGA) with peritoneal metastases.
Methods
Retrospective review of genomic analyses and outcomes in patients with CRC or HGA with peritoneal metastases at a high‐volume center from 2012 to 2019.
Results
Ninety‐two patients (57 CRC, 35 HGA) were identified. Overall survival was longer for CRC (52.8 vs. 30.5 months, p = 0.03), though rates of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) were similar. Multiple genes were more frequently mutated in CRC, including KRAS (51% vs. 29%, p = 0.04), TP53 (47% vs. 20%, p < 0.01), and APC (46% vs. 6%, p < 0.01). For CRC, multivariate regression showed an increased hazard ratio (HR) with increasing peritoneal cancer index (1.06 [1.01–1.11], p = 0.02) and a decreased HR following CRS/HIPEC (0.30 [0.11–0.80], p = 0.02). PIK3CA mutation associated with significantly increased HR (3.62 [1.06–12.41], p = 0.04), though only in non‐CRS/HIPEC patients. Multivariate analysis in the HGA group showed a benefit following CRS/HIPEC (0.18 [0.06–0.61], p = 0.01) and for mucinous disease (0.38 [0.15–0.96], p = 0.04), while there was an increased HR with TP53 mutation (6.89 [2.12–22.44], p < 0.01).
Conclusion
CRC and HGA with peritoneal spread have distinct mutational profiles. PIK3CA and TP53 mutations are associated with survival for CRC or HGA with peritoneal metastases, respectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Biological Sciences Division, University of Chicago, Chicago, Illinois, USA.
- Ben May Department of Cancer Research, Biological Sciences Division, University of Chicago, Chicago, Illinois, USA.
- Department of Medicine, Biological Sciences Division, University of Chicago, Chicago, Illinois, USA.
- Department of Surgery, Division of Surgical Oncology, Yale University, Hew Haven, CT, USA.
- Department of Surgery, Division of Surgical Oncology, University of California Irvine, Orange, California, USA.
ORCID-Profile: Oliver S Eng
Zitieren
APA
Morgan, R. B., Dhiman, A., Sood, D., Ong, C. T., Wu, X., Shergill, A., Polite, B., Turaga, K. K., & Eng, O. S. (2023). Mutational profiles and prognostic impact in colorectal and high‐grade appendiceal adenocarcinoma with peritoneal metastases. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27203
Vancouver
Morgan RB, Dhiman A, Sood D, Ong CT, Wu X, Shergill A, et al. Mutational profiles and prognostic impact in colorectal and high‐grade appendiceal adenocarcinoma with peritoneal metastases. Journal of Surgical Oncology. 2023. doi:10.1002/jso.27203
BibTeX
@article{Morgan2023,
author = {Morgan, Ryan B and Dhiman, Ankit and Sood, Divya and Ong, Cecilia T and Wu, Xiaoyang and Shergill, Ardaman and Polite, Blase and Turaga, Kiran K and Eng, Oliver S},
title = {Mutational profiles and prognostic impact in colorectal and high‐grade appendiceal adenocarcinoma with peritoneal metastases},
journal = {Journal of Surgical Oncology},
year = {2023},
doi = {10.1002/jso.27203}
}
EUVIMED